Pharmaxis has announced that two Phase 3 trials of its Bronchitol inhaled mannitol in patients with cystic fibrosis demonstrated significant improvement in lung function with Bronchitol compared to the control group. The company also cites positive patient response to the DPI. Bronchitol has received orphan drug status in both the US and Europe. Read the company’s press release.
